Navigation Links
Bionovo Announces Third Quarter 2011 Highlights and Financial Results
Date:11/10/2011

tency compared to the highest dose tested in our Phase 2 study. This level of efficacy at 4 weeks is equivalent to or superior to estrogen-based hormone therapy.
  • The Company successfully completed non-clinical toxicology studies of Menerba in two animal species.  As expected, no serious adverse events or toxicities were observed to date from these studies, at doses much higher than are being tested in the Phase 3 clinical trial. The drug was well tolerated by the animals.
  • The Company has completed the manufacture of the requisite ten batches for the Phase 3 clinical trial of Menerba, and demonstrated to the FDA excellent consistency and quality.

  • Third Quarter ResultsTotal operating expenses for the three months ending September 30, 2011 were $6.4 million compared to $4.7 million for the same period in 2010. Total operating expenses for the third quarter included manufacturing costs at the Company's cGMP manufacturing facility in Hayward, California for ten clinical batches of Menerba, clinical trial costs for the tolerability trial assessing the safety and tolerability of higher doses of Menerba and other costs in preparation for the Company's Phase 3 trial of Menerba.

    The Company reported a net loss for the three months ended September 30, 2011 of $3.9 million, or $0.07 per share, compared with a net loss of $4.6 million, or $0.21 per share, for the same period in 2010.  The difference in net loss is primarily due to the increase in operating expenses as described above offset by the change in fair value of the Company's warrant liability representing a gain of $2.3 million included in non-operating income for the three months ended September 30, 2011.

    The Company ended the quarter with $8.1 million in cash, cash equivalents and short term investments, and began the quarter with $13.0 million, a difference of $4.9 million. The cash balance at the end of the quarter reflects the proceeds of the Company'
    '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
    2. Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
    3. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
    4. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
    5. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
    6. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
    7. Bionovo to Announce First Quarter Financial Results on Wednesday, May 11, 2011
    8. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
    9. Bionovo Announces 2010 Highlights and Year-End Financial Results
    10. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    11. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
    (Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
    (Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
    Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
    (Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
    (Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
    (Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
    (Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
    Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
    ... GLASSBORO, N.J., Aug. 25 Getting a firmer, healthier, better-looking body -- in ... a fitness plan that will truly help you reach your personal goals. , ... , , , An ... you will dedicate to achieving your fitness goals and stick with it! , ...
    ... , Study Suggests Division, Ambivalence and Hesitancy ... ANN ARBOR, Mich., Aug. 25 Americans lack confidence that healthcare ... to a survey released today by the Thomson Reuters. , ... healthcare reform, addresses a wide range of issues including the cost ...
    ... Most OTC hemorrhoid ... your hemorrhoids faster. , ... York, NY (PRWEB) August 26, 2009 -- Many drug companies desperately do not want revealed ... damage. "Steroid creams in particular may cause permanent damage or ulceration of perianal skin," states ...
    ... , , Updated Report ... , , LANDOVER, Md., Aug. 25 ... conditions, the school-house is a focal point for managing their diseases. ... and Allergy Foundation of America (AAFA) has released a report assessing ...
    ... ONCOLOGY: Human breast cancer hit for six: key role for ... and colleagues, at the University of Colorado School of Medicine, ... mouse models and analysis of human cells, implicating the protein ... that plays a central role in development, is not expressed ...
    ... , , OMAHA, ... its private equity sponsor, Diamond Castle Holdings and the Company,s Management ... debt and renegotiated favorable new terms and conditions with its banking ... As a result of this transaction, overall debt for YORK ...
    Cached Medicine News:Health News:Why Weight for a Better Body? 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 3Health News:Introducing anuleaf AD, a New FDA-Approved Hemorrhoid Treatment 2Health News:Deja Vu for Six States on Annual Asthma & Allergy Honor Roll 2Health News:Deja Vu for Six States on Annual Asthma & Allergy Honor Roll 3Health News:JCI table of contents: Aug. 24, 2009 2Health News:JCI table of contents: Aug. 24, 2009 3Health News:JCI table of contents: Aug. 24, 2009 4Health News:JCI table of contents: Aug. 24, 2009 5Health News:JCI table of contents: Aug. 24, 2009 6Health News:YORK Label Announces Continued Investment in the Company 2
    ... to use and transportable, the Dornier Compact Delta ... user and the patient. The systems shock source ... zone accuracy and avoid the risk of misalignment. ... unique due to its motorized lateral and horizontal ...
    The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
    Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
    The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
    Medicine Products: